Open AccessThis article is
- freely available
Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer
Department of Systems Medicine, University of “Tor Vergata”, Via Montpellier 1, Rome 00133, Italy
* Author to whom correspondence should be addressed.
Received: 1 June 2012; in revised form: 18 June 2012 / Accepted: 20 June 2012 / Published: 25 June 2012
Abstract: Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), a member of the TNF superfamily, interacts with its functional death receptors (DRs) and induces apoptosis in a wide range of cancer cell types. Therefore, TRAIL has been considered as an attractive agent for cancer therapy. However, many cancers are resistant to TRAIL-based therapies mainly due to the reduced expression of DRs and/or up-regulation of TRAIL pathway-related anti-apoptotic proteins. Compounds that revert such defects restore the sensitivity of cancer cells to TRAIL, suggesting that combined therapies could help manage neoplastic patients. In this article, we will focus on the TRAIL-sensitizing effects of natural products and synthetic compounds in colorectal cancer (CRC) cells and discuss the molecular mechanisms by which such agents enhance the response of CRC cells to TRAIL.
Keywords: DR4; DR5; caspase-8; p53; CHOP; survivin; extrinsic pathway; intrinsic pathway; chemotherapeutics; natural products
Citations to this Article
Cite This Article
MDPI and ACS Style
Stolfi, C.; Pallone, F.; Monteleone, G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. Int. J. Mol. Sci. 2012, 13, 7886-7901.
Stolfi C, Pallone F, Monteleone G. Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer. International Journal of Molecular Sciences. 2012; 13(7):7886-7901.
Stolfi, Carmine; Pallone, Francesco; Monteleone, Giovanni. 2012. "Molecular Targets of TRAIL-Sensitizing Agents in Colorectal Cancer." Int. J. Mol. Sci. 13, no. 7: 7886-7901.